Rate My Professor Dimitra Micha

Dimitra Micha is an Assistant Professor in Human Genetics at Amsterdam UMC, location VUmc, where she also holds the position of Principal Investigator and heads the Center for Connective Tissue Diseases within the Department of Human Genetics. She obtained her PhD in clinical pharmacology from the University of Manchester in 2010. Since establishing her research group in 2016, she has directed investigations into genetic disorders impacting bone and cardiovascular tissues, specializing in Osteogenesis Imperfecta (OI), Fibrodysplasia Ossificans Progressiva (FOP), and other monogenic skeletal fragility and dysplasia disorders. Her work encompasses identifying novel genetic causes, developing preclinical models from patient-derived skin cells to generate osteoblasts and smooth muscle cells, and facilitating drug screening and therapy development. Micha coordinates the international OI variant database, serves on the scientific board of the Osteogenesis Imperfecta Federation Europe (OIFE), and is a member of the scientific committee for the 15th International Conference on Osteogenesis Imperfecta.

Key contributions include the discovery of PLS3 mutations causing X-linked osteoporosis with fractures, published in the New England Journal of Medicine in 2013, and bi-allelic KDELR2 variants associated with OI in the American Journal of Human Genetics in 2020. Additional significant publications feature SMAD2 mutations linked to arterial aneurysms and dissections in Human Mutation (2015), inhibition of TGF-beta signaling reducing osteogenic differentiation in FOP fibroblasts in Bone (2016), and PIH1D3 mutations resulting in X-linked primary ciliary dyskinesia in the American Journal of Human Genetics (2017). Her research has secured multiple grants, led to several PhD promotions, and advanced molecular diagnostics, disease mechanisms understanding, and therapeutic strategies, including a novel Col1a1 knockout mouse model for OI type 1 and bone organoids for modeling rare genetic skeletal disorders. Through collaborations with clinical teams at the Amsterdam Bone Center and Rare Bone Disease Center, her efforts enhance patient care and translational research in connective tissue diseases.